Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC

CONCLUSION: Co-occurring EGFR p.E709X mutation mediates primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients but remained sensitive to afatinib. A personalized treatment strategy should be undertaken based on the co-existing EGFR p.E709X mutation status.PMID:38578683 | DOI:10.1158/1078-0432.CCR-23-3302

Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Lanlan Pang Yihua Huang Weitao Zhuang Yaxiong Zhang Jun Liao Yue Hao Feng Hao Guoqian Wang Ze-Xin Chase Chen Yu Zhu Mengzhen Li Zhengbo Song Bo Peng Deng Jing Li Li Zhang Wenfeng Fang Source Type: research